利妥昔单抗治疗嗜酸性肉芽肿性多血管炎:观察性研究的系统综述
可评估患者中超过80%达到完全或部分缓解,pANCA阳性亚组完全缓解率有更高趋势,但研究异质性限制结果解读与临床转化。
要点
- 可评估EGPA患者中超过80%使用利妥昔单抗后达到完全或部分缓解。
- pANCA阳性亚组显示完全缓解率更高的趋势。
- 研究设计、入组标准与结局定义异质性大,限制证据可比性与临床推广。
核心结论
- 多数可评估的接受利妥昔单抗治疗的EGPA患者达到完全缓解,但异质性妨碍结果清晰解读并限制临床转化。
研究设计与样本
- 系统综述,检索PubMed/MEDLINE、Scopus、Web of Science和Cochrane图书馆数据库中利妥昔单抗相关文献,并广泛检索其他生物制剂文献。
主要发现
- 可评估患者中超过80%达到完全或部分缓解。
- pANCA阳性亚组完全缓解率有更高趋势。
关键数值与推荐
- 可评估EGPA患者中超过80%使用利妥昔单抗后达到完全或部分缓解。
- pANCA阳性亚组完全缓解率有更高趋势。
临床怎么用
- 利妥昔单抗可使多数可评估EGPA患者达到完全或部分缓解,但研究异质性限制结果向临床实践的直接转化。
局限性
- 研究设计、入组标准、结局定义和测量方法存在差异,使利妥昔单抗与其他生物制剂研究数据的比较不可靠。
- 异质性来源妨碍结果清晰解读并限制其临床可转移性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyse the available evidence about the use of rituximab (RTX) and other biologic agents in eosinophilic granulomatosis with polyangiitis (EGPA) patients and to provide useful findings to inform the design of future, reliable clinical trials. METHODS: A systematic review was performed. A systematic search was conducted in PubMed/MEDLINE, Scopus, Web of Science and the Cochrane library databases on RTX, and an extensive literature search was conducted on other biologic agents. RESULTS: Forty-five papers pertinent to our questions were found: 16 retrospective cohort studies, 8 case series, 3 prospective cohort studies and 18 single case reports, for a total of 368 EGPA patients. More than 80% of evaluable patients achieved complete or partial remission with a tendency towards a higher rate of complete response in the pANCA-positive subgroup. CONCLUSION: Although the majority of the evaluable EGPA patients treated with RTX appears to achieve complete remission, we strongly believe that a number of sources of heterogeneity impair a clear interpretation of results and limit their transferability in clinical practice. Differences in design, enrolment criteria, outcome definition and measurement make a comparison among data obtained from studies on RTX and other biologic agents unreliable.
引用
- Menditto VG, Rossetti G, Olivari D, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies. Rheumatology (Oxford). 2021. PMID: 33471122. doi:10.1093/rheumatology/keab046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。